S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis
Faekah Gohar(Boston Children's Hospital), Dirk Holzinger(University of Duisburg-Essen), Lucy R. Wedderburn(Great Ormond Street Hospital), Dirk Foell(Klinik für Schlafmedizin), Michael Frosch(University Hospital Münster), Gerd Horneff(Asklepios Klinik Sankt Augustin), R. ten Cate(Leiden University), Koert M. Dolman(Reade), Halima Moncrieffe(Cincinnati Children's Hospital Medical Center), Simona Ursu(Universität Ulm), Femke H. M. Prince(Brigham and Women's Hospital), Marion A. J. van Rossum(Reade), Esther P A H Hoppenreijs(Radboud University Nijmegen), Lisette W. A. van Suijlekom‐Smit(Erasmus MC - Sophia Children’s Hospital), Janneke Anink(Boston Children's Hospital)
Cited by 38
Related Papers
Activated STING in a Vascular and Pulmonary Syndrome
|New England Journal of Medicine|2014|1.4k
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
|Journal of Clinical Investigation|2018|519
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients
|Arthritis & Rheumatology|2014|430
Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases
|Journal of Clinical Investigation|2019|238